Canadian Expert Group consensus recommendations: ... [Curr Oncol. 2011] - PubMed - NCBI

Curr Oncol. 2011 Aug;18(4):e180-4.

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.

Aubin F, Gill S, Burkes R, Colwell B, Kamel-Reid S, Koski S, Pollett A, Samson B, Tehfe M, Wong R, Young S, Soulières D.

Source

Centre Hospitalier de l’Université de Montréal, Montreal, QC.

Abstract

Monoclonal antibodies against the epidermal growth factor receptor (anti-egfr) when used in the treatment of metastatic colorectal cancer are associated with improved survival. Patients whose tumours harbor a KRAS mutation in codon 12 or 13 have been shown not to benefit from anti-egfr antibodies. The importance of KRAS mutation status in the management of patients with metastatic colorectal cancer has led to the elaboration of Canadian consensus recommendations on KRAS testing, with the aim of standardizing practice across Canada and reconciling testing access with the clinical demand for testing. The present guidelines were developed at a Canadian consensus meeting held in Montreal in April 2010. The best available evidence and expertise were used to develop recommendations for various aspects of KRAS testing, including indications and timing for testing, sample requirements, recommendations for reporting requirements, and acceptable turnaround times.

PMID:

21874108

[PubMed - in process]

PMCID: PMC3149550

Canadian Expert Group consensus recommendations: … [Curr Oncol. 2011] – PubMed – NCBI

National Guideline Clearinghouse | Consensus treatment recommendations for late-onset Pompe disease.

full-text â–º
National Guideline Clearinghouse | Consensus treatment recommendations for late-onset Pompe disease.

December 31, 2012

Guideline Title

Consensus treatment recommendations for late-onset Pompe disease.

Bibliographic Source(s)

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012 Mar;45(3):319-33. [108 references] PubMed

Guideline Status

This is the current release of the guideline.

Muscle Nerve. 2012 Mar;45(3):319-33. doi: 10.1002/mus.22329. Epub 2011 Dec 15.

Consensus treatment recommendations for late-onset Pompe disease.

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT; AANEM Consensus Committee on Late-onset Pompe Disease.

Source

Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.

Abstract

INTRODUCTION:

Pompe disease is a rare, autosomal recessive disorder caused by deficiency of the glycogen-degrading lysosomal enzyme acid alpha-glucosidase. Late-onset Pompe disease is a multisystem condition, with a heterogeneous clinical presentation that mimics other neuromuscular disorders.

METHODS:

Objective is to propose consensus-based treatment and management recommendations for late-onset Pompe disease.

METHODS:

A systematic review of the literature by a panel of specialists with expertise in Pompe disease was undertaken.

CONCLUSIONS:

A multidisciplinary team should be involved to properly treat the pulmonary, neuromuscular, orthopedic, and gastrointestinal elements of late-onset Pompe disease. Presymptomatic patients with subtle objective signs of Pompe disease (and patients symptomatic at diagnosis) should begin treatment with enzyme replacement therapy (ERT) immediately; presymptomatic patients without symptoms or signs should be observed without use of ERT. After 1 year of ERT, patients’ condition should be reevaluated to determine whether ERT should be continued.
Copyright © 2011 Wiley Periodicals, Inc.

PMID:

22173792

[PubMed - indexed for MEDLINE] 

Consensus treatment recommendations for late-on… [Muscle Nerve. 2012] – PubMed – NCBI